Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Juying Jiao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4435-9931; OpenAlex author ID A5063006365, A5134852279. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. Role of PTK6 in the diagnosis, prognosis, and immune infiltration of pancreatic cancer based on evidence from bioinformatics analysis and experimental validati… Co-author DOI 10.1007/s12672-026-05115-9↗
  2. DNA methylation-mediated ADA overexpression drives pancreatic cancer progression. First author DOI 10.1007/s12672-025-04014-9↗
  3. Berberine chloride suppresses pancreatic adenocarcinoma proliferation and growth by targeting inflammation-related genes: an in silico analysis with in vitro a… First author DOI 10.1007/s00280-024-04663-7↗
  4. KIF20B and MET, hub genes of DIAPHs, predict poor prognosis and promote pancreatic cancer progression. Co-author DOI 10.1016/j.prp.2023.155046↗
  5. "Huanglianjiedu Decoction" Against Pancreatic Adenocarcinoma Proliferation of by Downregulating the PI3K/AKT/mTOR and MAPK/ERK1/2 Signaling Pathways. Co-author DOI 10.1177/2515690x241291381↗
  6. EIF2Ss, a Novel c-Myc-Correlated Gene Family, is Associated with Poor Prognosis and Immune Infiltration in Pancreatic Adenocarcinoma. Co-author DOI 10.31083/j.fbl2903119↗
  7. Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation. Co-author DOI 10.1186/s10020-023-00648-z↗
  8. Matrine injection inhibits pancreatic cancer growth via modulating carbonic anhydrases- a network pharmacology-based study with in vitro validation. Co-author DOI 10.1016/j.jep.2021.114691↗
  9. Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer. Co-author DOI 10.1016/j.jep.2022.115516↗
  10. HELLS serves as a poor prognostic biomarker and its downregulation reserves the malignant phenotype in pancreatic cancer. Co-author DOI 10.1186/s12920-021-01043-5↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chien‐shan Cheng · 8 shared papers, 2021–2024 · strength 1.66
  2. Zhen Chen · 5 shared papers, 2021–2024 · strength 1.00
  3. Peiwen Yang · 4 shared papers, 2022–2026 · strength 1.00
  4. Linjie Ruan · 4 shared papers, 2023–2024 · strength 0.89
  5. Zhangqi Cao · 4 shared papers, 2021–2024 · strength 0.83
  6. Fengjiao Wang · 3 shared papers, 2023–2024 · strength 0.65
  7. Panling Xu · 3 shared papers, 2022–2024 · strength 0.61
  8. Yanhua Jing · 3 shared papers, 2021–2024 · strength 0.59
  9. Ke Zhang · 2 shared papers, 2024 · strength 0.43
  10. Shu Dong Ma · 2 shared papers, 2022–2024 · strength 0.42
  11. Shu-Lin Yu · 1 shared paper, 2026 · strength 0.36
  12. Yue Fan · 1 shared paper, 2026 · strength 0.36
  13. Fang Wang · 1 shared paper, 2026 · strength 0.36
  14. Weijie Xu · 1 shared paper, 2025 · strength 0.33
  15. Jingyi Zeng · 1 shared paper, 2025 · strength 0.33
  16. Lianyu Chen · 1 shared paper, 2024 · strength 0.26
  17. He Ba · 1 shared paper, 2024 · strength 0.24
  18. Zhen Chen · 1 shared paper, 2024 · strength 0.24
  19. Hao Chen · 1 shared paper, 2022 · strength 0.19
  20. Ping Li · 1 shared paper, 2022 · strength 0.19
  21. Xiaoyan Zhu · 1 shared paper, 2022 · strength 0.16
  22. Fengjiao Wang · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.